FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

AHK-Cu

Ala-His-Lys-Cu / Copper Peptide AHK

Recovery & Repair

AHK-Cu (Copper Tripeptide Ala-His-Lys-Cu) is a copper-binding tripeptide variant consisting of alanine-histidine-lysine complexed with a copper(II) ion, studied for its potential role in hair growth stimulation and skin rejuvenation. It is structurally related to the more extensively studied GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) but with alanine substituted for glycine at the first position, potentially altering its receptor interactions and biological activity profile. Research applications focus primarily on dermal papilla cell stimulation, wound healing, and cosmetic anti-aging formulations.

Meccanismo d'azione

Synthetic copper-binding tripeptide analog of GHK-Cu with alanine substituted for glycine. Stimulates collagen synthesis and dermal fibroblast proliferation. May offer enhanced stability over GHK-Cu while maintaining copper-dependent tissue remodeling activity.

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Research protocols mirror GHK-Cu. Topical: 1-2% concentration. Injectable protocols not well-established. Primarily studied in cosmetic formulations.

Note di ricerca

Clinical Research Status

AHK-Cu has significantly less published clinical research compared to its well-studied relative GHK-Cu, with most available data coming from in vitro cell culture studies and cosmetic ingredient characterization rather than formal clinical trials. Patent literature and cosmetic industry research reports suggest efficacy in hair follicle stimulation, but independent peer-reviewed clinical validation remains limited. It is available as a cosmetic ingredient and in topical hair growth formulations, but has not been evaluated by the FDA for any medical indication.

Key Published Findings

In vitro studies on human dermal papilla cells demonstrate that AHK-Cu stimulates proliferation and increases production of vascular endothelial growth factor (VEGF) and other growth factors associated with hair follicle angiogenesis. Comparative studies suggest AHK-Cu may have superior hair growth stimulation activity compared to GHK-Cu in certain cell culture models, possibly due to different binding dynamics at the cellular level. The copper ion is essential for activity, participating in extracellular matrix remodeling through lysyl oxidase activation and superoxide dismutase function.

Safety Profile

Copper peptides generally have an excellent topical safety profile, with AHK-Cu showing no significant irritation or sensitization in available patch testing data. Systemic copper toxicity is not a concern at concentrations used in topical formulations (typically 0.001-0.1%). As with all copper peptides, high concentrations may produce a blue-green discoloration of skin or products, and interactions with ascorbic acid (vitamin C) can cause oxidative degradation of both compounds when co-formulated.

Comparison to Related Compounds

GHK-Cu is the most extensively studied copper peptide with over 100 published papers documenting wound healing, anti-inflammatory, and anti-aging effects, while AHK-Cu has a much smaller research base. The alanine substitution in AHK-Cu may provide different tissue specificity or potency for hair follicle applications compared to GHK-Cu's broader tissue effects. Both copper peptides differ fundamentally from minoxidil (a potassium channel opener) and finasteride (a 5-alpha reductase inhibitor), working through growth factor and extracellular matrix pathways rather than vascular or hormonal mechanisms.

Community Observations

Hair loss communities have shown growing interest in AHK-Cu as an addition to topical hair growth regimens, often combined with GHK-Cu, minoxidil, and microneedling protocols. Users report that results are gradual and modest, typically requiring 3-6 months of consistent application to assess efficacy. The peptide is available from specialized cosmetic ingredient suppliers and is increasingly appearing in commercial hair growth serums, though concentration standardization varies significantly between products.

Semplifichro

~30-60 minutes

Riconcimimento

Bacteriostatic water (BAC)

Conservazione

Lyofilizzato

Refrigerate 2-8C up to 12 months.

Riconcimato

Refrigerate 2-8C. Use within 14 days.

Stato legale USA

Cosmetic/research ingredient

Anche noto come

Ala-His-Lys-CuCopper Peptide AHK

Domande frequenti

Che cos'è AHK-Cu?

AHK-Cu (Copper Tripeptide Ala-His-Lys-Cu) is a copper-binding tripeptide variant consisting of alanine-histidine-lysine complexed with a copper(II) ion, studied for its potential role in hair growth stimulation and skin rejuvenation. It is structurally related to the more extensively studied GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) but with alanine substituted for glycine at the first position, potentially altering its receptor interactions and biological activity profile. Research applications focus primarily on dermal papilla cell stimulation, wound healing, and cosmetic anti-aging formulations.

Come agisce AHK-Cu?

Synthetic copper-binding tripeptide analog of GHK-Cu with alanine substituted for glycine. Stimulates collagen synthesis and dermal fibroblast proliferation. May offer enhanced stability over GHK-Cu while maintaining copper-dependent tissue remodeling activity.

Qual è lo stato normativo di AHK-Cu negli Stati Uniti?

Cosmetic/research ingredient

Qual è l'emivita di AHK-Cu?

~30-60 minutes

Con quali altri nomi è noto AHK-Cu?

Ala-His-Lys-Cu, Copper Peptide AHK

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità